Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Falavarjani, Khalil Ghasemi; Nguyen, Quan Dong

doi:10.1038/eye.2013.107

Cited by 759 publications

(568 citation statements)

References 85 publications

Supporting

Mentioning

505

Contrasting

Unclassified

Order By: Relevance

“…The dose of 12-or 15-HETE was chosen according to what was detected previously in the vitreous of patients with DR, 50 ng/ml ( ‫ف‬ 0.1 M) ( 21 ). ( 4,5 ). Likewise, cumulative risks of cataract and glaucoma, as well as local immunosuppression, are frequently associated with corticosteroid intravitreal therapy ( 6,7 ).…”

Section: Animal Preparation and Experimental Designmentioning

confidence: 99%

A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase

Ibrahim

Elshafey

Hassan

et al. 2015

Journal of Lipid Research

View full text Add to dashboard Cite

Diabetic retinopathy (DR), the most prevalent microvascular complication of diabetes, is responsible for over 10,000 new cases of blindness every year in the United States alone ( 1 ). The risk of vision loss increases with the development of diabetic macular edema and/or retinal neovascularization (NV), the former being a direct consequence of blood-retinal barrier (BRB) dysfunction and the latter the result of widespread retinal ischemia ( 2 ).For years, signifi cant effort has been invested in elucidating the mechanisms that underlie destructive preretinal NV in DR ( 3 ). Nonetheless, considerably less is known about the molecular events that lead to BRB dysfunction that is characterized by enhanced retinal vascular permeability and recruitment of infl ammatory cells. Moreover, existing regimens of treatment carry nonspecifi c adverse effects. These include increased risk of thromboembolic incidence, neuronal toxicity, and geographic atrophy with anti-vascular endothelial growth factor (VEGF) therapies

show abstract

Section: Animal Preparation and Experimental Designmentioning

confidence: 99%

A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase

Ibrahim

Elshafey

Hassan

et al. 2015

Journal of Lipid Research

View full text Add to dashboard Cite

show abstract

“…Even though anti-VEGF interventions have shown better outcomes than alternative treatments, limitations to anti-VEGF therapies may exist, including short duration of action, local and systemic adverse effects, and poor response in a significant percentage of patients (12)(13)(14). Furthermore, the production of other angiogenic factors may cause resistance to anti-VEGF therapies.…”

mentioning

confidence: 99%

Therapeutic Potential of Anti-Angiogenic Multitarget N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy

et al. 2015

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) blockers have been developed for the treatment of proliferative diabetic retinopathy (PDR), the leading cause of visual impairments in the working-age population in the Western world. However, limitations to anti-VEGF therapies may exist because of the local production of other proangiogenic factors that may cause resistance to anti-VEGF interventions. Thus, novel therapeutic approaches targeting additional pathways are required. Here, we identified a sulfated derivative of the Escherichia coli polysaccharide K5 [K5-N,OS(H)] as a multitarget molecule highly effective in inhibiting VEGF-driven angiogenic responses in different in vitro, ex vivo, and in vivo assays, including a murine model of oxygen-induced retinopathy. Furthermore, K5-N,OS(H) binds a variety of heparin-binding angiogenic factors upregulated in PDR vitreous humor besides VEGF, thus inhibiting their biological activity. Finally, K5-N,OS(H) hampers the angiogenic activity exerted in vitro and in vivo by human vitreous fluid samples collected from patients with PDR. Together, the data provide compelling experimental evidence that K5-N,OS(H) represents an antiangiogenic multitarget molecule with potential implications for the therapy of pathologic neovessel formation in the retina of patients with PDR.

show abstract

“…Currently more data are becoming available due to wide antiangiogenic agents use for the treatment of eye diseases, and safety data review for intravitreal injection of common anti-VEGF agents was conducted [11] . VEGF plays an important role in adult homeostasis.…”

Section: Afliberceptmentioning

confidence: 99%

Pharmacovigilance in Intraocular Antiangiogenic Therapy

Shahsuvaryan

2015

International Journal of Ophthalmic Research

View full text Add to dashboard Cite

pegaptanib sodium, ranibizumab, aflibercept. The articles of high or medium clinical relevance were selected for review. Results: Almost uniformly all trial evaluating ocular safety of antiangiogenic agents reveal the serious side effects including geographic atrophy, pigment epithelial tear, ocular hemorrhage despite the fact that the incidence is low. Ocular safety concern in intraocular pharmacotherapy by anti-angiogenic agents has a strong body of clinical evidence, resulting in plenty of peer reviewed clinical articles. Conclusion: Currently available findings obviate the need to raise awareness about chemical compound-related ocular side effects in patients with eye diseases treated by antiangiogenic agents. Hopefully that noninvasive therapeutic options will become available soon. INTRODUCTIONVascular endothelial growth factor (VEGF) plays an important role not only in the pathophysiology of several light-threatening retinal disorders such as age-related macular degeneration, retinal vein occlusion, diabetic macular edema and proliferative diabetic retinopathy contributing to increased permeability across both the blood-retinal and blood-brain barrier, but also in physiology of the eye [1] . ABSTRACTContext: Currently several antiangiogenic agents are being widely and successfully used for the treatment of eye diseases like neovascular macular degeneration, retinal vein occlusion and diabetic macular edema. The discovery of anti-VEGF (Vascular endothelial growth factor) agents has revolutionized the treatment of these conditions. Ophthalmology has witnessed an explosion in the number of intravitreal injections delivered to patients over the past 10 years, driven in large part by the introduction and rapid incorporation of therapy with anti-VEGF agents. Objective: Taking into consideration that VEGF plays an important role not only in the pathophysiology of several sight-threatening retinal disorders such as age-related macular degeneration, retinal vein occlusion, diabetic macular edema and proliferative diabetic retinopathy, but also in the physiology of the eye, and that more data are becoming available in intraocular antiangiogenic therapy, chemical compound-related ocular side effects across multiple antiangiogenic agents should be analyzed critically. Methods: A comprehensive literature search was conducted on Medline, PubMed, and Google Scholar databases in February 2015. Search temporal limits included articles published from 2005 to 2015 with the purpose of providing the most recent evidence. Studies were queried using the following keywords in various combinations: antiangiogenics in eye diseases, intravitreal pharmacotherapy by anti-VEGF, adverse effects, potential ocular hazards, bevacizumab,

show abstract

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Cited by 759 publications

References 85 publications

A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase

A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase

Therapeutic Potential of Anti-Angiogenic Multitarget N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy

Pharmacovigilance in Intraocular Antiangiogenic Therapy

Contact Info

Product

Resources

About